Canopy Growth (NASDAQ:CGC) is a premier Canadian cannabis company. Granted, Canopy Growth isn’t in perfect financial condition. That’s likely true for every canna-business. Canopy Growth stock can rise as the company improves.I’m not suggesting that 2024 will be bubble-icious like 2018 was. Canopy Growth’s shareholders should be cautious and avoid price chasing and over-investing. Canopy Growth’s recent results show progress in closing the profitability gap.Canopy Growth: Don’t Expect Too MuchWhen I said, “ ...

Canopy USA completes acquisition of Jetty and advances acquisition of Wana SMITHS FALLS, ON, June 4, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that the option to acquire all of the issued and outstanding Class E subordinate voting shares (the "Fixed Shares") of Acreage Holdings, Inc. ("Acreage") has been exercised in accordance wit ...

Key PointsCanopy Growth prioritizes profitability over pure revenue growth, which is evident in its divestitures and focus on higher-margin segments like medical cannabis and vaporizers.While the Canadian market presents challenges, international markets are driving significant revenue gains for the company.Acquisitions and strategic restructuring will allow Canopy Growth to capitalize on potential US federal legalization, though the timeline remains uncertain.5 stocks we like better than Canopy GrowthCanop ...

财务数据和关键指标变化 - 第四季度合并净收入为7300万加元,同比增长16% [14] - 全年毛利率为27%,现金毛利率为35% [14] - 第四季度调整后EBITDA亏损1500万加元,同比改善63% [14] - 第四季度自由现金流流出2300万加元,同比改善75% [14] 各条业务线数据和关键指标变化 - 加拿大业务第四季度收入3700万加元,同比增长4% [15] - 加拿大医疗业务收入同比增长16% [15] - 加拿大成人用途B2B业务收入同比下降4% [15] - 加拿大业务第四季度毛利率为0%,现金毛利率为13% [16] - 国际市场业务第四季度收入同比增长32% [17] - Storz & Bickel第四季度收入同比增长43% [17] 各个市场数据和关键指标变化 - 波兰业务第四季度实现三位数增长 [17] - 德国业务第四季度实现双位数增长 [17] - 澳大利亚Storz & Bickel设备销售下降 [17] 公司战略和发展方向及行业竞争 - 公司实施资产轻型模式,专注核心优势并利用第三方扩大产能 [4] - 公司出售非大麻业务,全面聚焦大麻业务 [4] - 公司在加拿大、国际市场和Storz & Bickel业务均有良好表现 [5][6][7] - 公司加强财务状况,通过多项措施减少超过11亿加元债务 [6][19][20] - 公司计划在加拿大、国际市场和Storz & Bickel业务实现良好增长 [8][21] - 公司在美国市场通过Canopy USA战略加快布局 [11][12] - 预计大麻合法化将为公司带来重大机遇 [12] 管理层对经营环境和未来前景的评论 - 公司认为大麻是最令人兴奋的消费趋势之一 [4] - 公司对未来一年的表现充满信心,认为将是公司最好的一年 [7][13] - 公司认为加拿大市场、国际市场和Storz & Bickel业务均有良好增长前景 [8][21] - 公司对Canopy USA战略前景充满信心,认为将带来加速增长 [11][12] - 公司认为大麻合法化是行业的重大进步 [12] 其他重要信息 - 公司已实现2.8亿加元的累计成本节约,并计划在2025财年实现额外1000万至5000万加元的成本节约 [18] - 公司通过多项交易进一步改善财务状况,包括偿还短期债务、延长债务期限等 [19][20] 问答环节重要的提问和回答 问题1 **Aaron Grey 提问** 询问加拿大业务毛利率改善的时间节奏 [23] **Judy Hong 回答** 预计加拿大业务现金毛利率将在下半年达到中高30%水平,全年中高30%左右 [24] 问题2 **John Zamparo 提问** 询问公司如何看待剩余债务及偿还计划 [26] **Judy Hong 回答** 公司已消除短期债务,下一笔大额债务到期在2026年3月,公司有灵活性投资增长机会 [28] 问题3 **Yewon Kang 提问** 询问公司国际业务中美国CBD业务的情况 [30] **Judy Hong 回答** 公司正在将美国CBD业务转移至Canopy USA,未来不会再是Canopy的重点业务 [31]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $2.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $1.79, delivering a surprise of -297.78%.Over the last four quarters, the company h ...

财务表现 - 公司在Q4 FY2024实现21%的综合毛利率，较上年同期提升11,500个基点[4][8] - 公司在FY2024实现27%的综合毛利率，较上年同期提升4,600个基点[4][13] - 公司在FY2024实现经营亏损4.84亿加元，经调整EBITDA亏损5,890万加元，较上年同期分别改善84%和72%[4][11] - 公司在Q4 FY2024实现经营亏损1.07亿加元，经调整EBITDA亏损1,510万加元，较上年同期分别改善80%和63%[11] - 公司在FY2024实现自由现金流流出2.32亿加元，较上年同期改善43%[4][12] - 公司在Q4 FY2024实现自由现金流流出2,270万加元，较上年同期改善77%[10][12] - 公司采用了多种非公认会计准则(Non-GAAP)指标,包括调整后EBITDA、自由现金流、调整后毛利率等,用于管理和评估公司业务[31][32][33] 业务表现 - 加拿大医疗大麻业务在Q4 FY2024实现16%的收入增长，全年增长10%[5][14] - 国际市场大麻业务在Q4 FY2024实现32%的收入增长，全年增长6%[7][14] - Storz & Bickel在Q4 FY2024实现43%的收入增长，主要得益于新款Venty便携式雾化器的强劲销售[2][18] - 公司在FY2024的加拿大大麻业务毛利率提升至16%，主要得益于存货减值费用下降和运营成本降低[14] 战略发展 - 公司正在加快进入美国大麻市场的步伐,通过设立Canopy USA公司来实现这一目标,预计将带来相关成本和收益[40] - 公司正在推进对Acreage Holdings的收购,包括通过浮动股份安排和行使期权等方式,预计将在未来完成[40] - 公司还计划收购Wana Brands和Jetty Extracts等公司,以扩大在美国大麻市场的布局[40] - 公司正在与Huneeus 2017 Irrevocable Trust进行20亿美元的投资交易,以获得Canopy USA的额外股权[41] - 公司正在积极应对美国大麻相关法规的变化,包括联邦和州级层面,以把握市场机遇[40][41] - 公司正在努力提升内部控制,确保持续经营能力[41] - 公司正在拓展产品线,包括大麻和大麻衍生消费品,以满足不同市场需求[41] - 公司正在优化供应链和生产制造能力,以提高运营效率[41] - 公司正在积极应对各类诉讼和监管审查,力求妥善解决[41] 财务数据 - 公司2024财年第四季度收入为83,153千加元，同比增长5.4%[48] - 2024财年全年收入为343,934千加元，同比下降10.0%[48] - 2024财年全年毛利为80,882千加元，同比增加244.1%[49] - 2024财年全年经营亏损为228,714千加元，同比减亏15.3%[49] - 2024财年全年净亏损为675,795千加元，同比减亏79.6%[49] - 2024年3月31日现金及现金等价物余额为170,300千加元[48] - 2024年3月31日总资产为1,300,330千加元[48] - 2024年3月31日总负债为799,823千加元[48] - 2024年3月31日股东权益为500,507千加元[48] - 2024财年经营活动现金流出为281,950千加元[50] - 公司2024财年第三季度收入为72,788千加元，同比增长6.7%[51] - 公司2024财年第三季度调整后毛利率为21%，同比提升10个百分点[51] - 公司2024财年第三季度调整后EBITDA为-15,091千加元，亏损收窄[52] - 公司2024财年第三季度自由现金流为-22,709千加元，同比改善[53] - 公司2024财年第三季度加拿大大麻业务调整后毛利率为0%[54] - 公司2024财年第三季度国际大麻业务调整后毛利率为52%[54] - 公司2024财年第三季度Storz & Bickel业务调整后毛利率为41%[54] - 公司2024财年第三季度This Works业务调整后毛利率为0%[54] - 公司2024财年收入为297,146千加元，同比下降10.8%[51] - 公司2024财年调整后毛利率为27%，同比提升22个百分点[51]

Storz & Bickel® delivered its best Q4 revenue quarter, with net revenue increasing 43% as compared to Q4 2023 Canada medical cannabis net revenue increased 16% in Q4 FY2024 and 10% in FY2024 year-over-year            Canada cannabis Cost of Goods Sold decreased by 54% in FY2024 versus FY2023 Following recent balance sheet actions, the Company has no material debt obligation due until March 20261SMITHS FALLS, ON, May 30, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy", "Canopy Growth" or the "Company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38496 Canopy Growth Corporation (Exact name of registrant as specified in its charter) Canada N/A (State or other jurisdiction of (I.R.S ...

Canopy Growth Corporation (CGC) is scheduled to report fourth-quarter fiscal 2024 results on May 30 before the opening bell.Let’s consider a few factors that might have influenced this cannabis major’s results in this to-be-reported quarter. However, it’s worth examining CGC’s performance in the previous quarter first.Surprising History and Estimates at a GlanceIn the third quarter of fiscal 2024, the company reported a loss of $1.79 compared with the Zacks Consensus Estimate of a loss of 45 cents per share ...